Abstract Consumers, when buying health insurance, do not know the exact value of each treatment that they buy coverage for. This leads them to overvalue some treatments and undervalue others. We show that the insurance market cannot correct these mistakes. This causes research labs to overinvest in treatments that hardly add value compared to current best practice. The government can stimulate R&D in breakthrough treatments by excluding treatments with low value added from health insurance coverage. If the country is rich enough such a government intervention in a private health insurance market raises welfare.
| Original language | English |
|---|
| Place of Publication | Tilburg |
|---|
| Publisher | TILEC |
|---|
| Number of pages | 40 |
|---|
| Volume | 2013-008 |
|---|
| Publication status | Published - 2013 |
|---|
| Name | TILEC Discussion Paper |
|---|
| Volume | 2013-008 |
|---|
- cost effectiveness analysis
- pharmaceutical research and development
- health insurance